Screening for Maturity-Onset Diabetes of the Young (MODY)

Key Clinical Scenarios Warranting MODY Screening

• The American Diabetes Association recommends genetic testing for MODY in children and young adults who do not have typical characteristics of type 1 or type 2 diabetes and who often have a family history of diabetes in successive generations, suggestive of an autosomal dominant pattern of inheritance 1, 2
• Age at diagnosis is a key factor, with diabetes diagnosed at a young age (classically before age 25 years) being a primary indication for MODY screening 1
• A family history of diabetes in successive generations, indicating an autosomal dominant pattern of inheritance, is also a primary indication for MODY screening 1, 2
• Atypical diabetes presentation, with clinical features not characteristic of either type 1 or type 2 diabetes, is another key scenario warranting MODY screening 2, 3

Specific Clinical Features Suggesting MODY

• The absence of typical type 1 diabetes features, including negative diabetes-associated autoantibodies, is suggestive of MODY 3
• The absence of typical type 2 diabetes features, including non-obesity and lacking other metabolic syndrome features, is also suggestive of MODY 3
• Minimal or no defects in insulin action are often seen in MODY patients 1
• Stable, mild fasting hyperglycemia and stable A1C between 5.6% and 7.6% are common glycemic patterns in MODY patients 3

Special Populations Requiring MODY Screening

• All children diagnosed with diabetes in the first 6 months of life should have immediate genetic testing for neonatal diabetes, as 80-85% of diabetes cases in this age group have an underlying monogenic cause 1, 2, 4

Importance of Correct Diagnosis

• Correct diagnosis of MODY is crucial, as treatment implications differ significantly from those for type 1 and type 2 diabetes, with GCK-MODY typically requiring no treatment except sometimes during pregnancy 1
• HNF1A-MODY and HNF4A-MODY usually respond well to low doses of sulfonylureas 1
• HNF1B-MODY is associated with renal cysts and other organ malformations requiring specialized management 1

Recommended Approach to Testing

• Biomarker screening, including urinary C-peptide/creatinine ratio and antibody screening, may help determine who should undergo genetic testing 3
• Genetic testing is increasingly cost-effective and often covered by health insurance 3
• Specialist consultation with a center specializing in diabetes genetics is recommended to understand the significance of mutations and guide further evaluation, treatment, and genetic counseling 1

Common Pitfalls to Avoid

• Assuming autoantibody positivity rules out MODY is a common pitfall, as the presence of autoantibodies has been reported in patients with monogenic diabetes 3, 5
• Delaying testing can prevent years of inappropriate treatment, highlighting the importance of early genetic diagnosis 5

Clinical Features and Management of Maturity-Onset Diabetes of the Young (MODY)

Clinical Presentation and Symptoms

• The American Diabetes Association notes that GCK-MODY (MODY 2) is characterized by stable, non-progressive elevated fasting blood glucose, typically asymptomatic, with mild hyperglycemia (100-150 mg/dL) and a small rise in 2-hour plasma glucose during OGTT (<54 mg/dL), with rare microvascular complications 6, 7, 8, 9
• HNF1A-MODY (MODY 3) presents with a progressive insulin secretory defect, lowered renal threshold for glucosuria, and a large rise in 2-hour plasma glucose during OGTT (>90 mg/dL), with possible typical diabetes symptoms (polydipsia, polyuria, polyphagia) 6, 7, 9, 10
• HNF4A-MODY (MODY 1) is characterized by a progressive insulin secretory defect, possible history of large birth weight, and possible history of transient neonatal hypoglycemia 6, 7, 9
• HNF1B-MODY (MODY 5) is associated with renal developmental disorders, genitourinary abnormalities, pancreatic atrophy, and hyperuricemia and gout 6, 7, 9

Diagnosis

• Genetic testing is the gold standard for diagnosis, with biomarker screening (urinary C-peptide/creatinine ratio and antibody screening) helping to determine candidates for genetic testing, according to the American Diabetes Association 6
• OGTT patterns can help differentiate MODY subtypes, as noted by the American Diabetes Association 6, 7, 9

Management

• The American Diabetes Association recommends that GCK-MODY (MODY 2) typically requires no pharmacological treatment, with lifestyle modifications only, and possible treatment during pregnancy 6
• HNF1A-MODY (MODY 3) and HNF4A-MODY (MODY 1) are treated with first-line low-dose sulfonylureas, due to high sensitivity to sulfonylureas, with possible insulin therapy as the condition progresses, as recommended by the American Diabetes Association 6, 7, 9
• HNF1B-MODY (MODY 5) requires a multidisciplinary approach due to multi-organ involvement, with management of renal disease, treatment of hyperuricemia and gout, and possible insulin therapy, according to the American Diabetes Association 6, 7, 9

Management of Sulfonylureas in Maturity-Onset Diabetes of the Young (MODY)

MODY Subtype-Specific Sulfonylurea Management

• The American Diabetes Association recommends sulfonylureas as the first-line pharmacological treatment for HNF1A-MODY (MODY3) and HNF4A-MODY (MODY1) due to their high sensitivity to these medications, while GCK-MODY (MODY2) typically requires no treatment 11
• Low doses of sulfonylureas are highly effective as first-line therapy for HNF1A-MODY (MODY3) and HNF4A-MODY (MODY1) due to specific genetic mutations affecting insulin secretion 12, 13, 11
• GCK-MODY (MODY2) typically requires no pharmacological treatment due to stable, non-progressive elevated fasting blood glucose, with microvascular complications being rare in this subtype 12, 13, 11
• HNF1B-MODY (MODY5) often requires insulin therapy due to pancreatic atrophy, with a multidisciplinary approach necessary due to associated renal disease and other organ involvement 12
• Genetic testing is essential for accurate diagnosis and appropriate treatment selection, with consideration of MODY in non-obese patients diagnosed with diabetes at a young age with strong family history 11

Distinguishing Type 1 Diabetes from MODY

Key Clinical Red Flags Suggesting MODY Over Type 1 Diabetes

• Diabetes diagnosed before age 25 years with a strong multigenerational family history (autosomal dominant pattern—diabetes in successive generations) strongly suggests MODY rather than type 1 diabetes, according to the American Diabetes Association 14
• Type 1 diabetes typically lacks this consistent multigenerational pattern and presents more sporadically, as noted by the American Diabetes Association 15

Laboratory Workup to Distinguish Type 1 Diabetes from MODY

• Measure pancreatic autoantibodies (GAD65, IA-2, insulin autoantibodies, ZnT8) to exclude autoimmune type 1 diabetes, as recommended by the American Academy of Pediatrics 16
• Type 1 diabetes shows progressive β-cell destruction with undetectable C-peptide over time, whereas MODY may have preserved pancreatic β-cell function, according to the American Diabetes Association 15

Genetic Testing and Treatment Implications

• Genetic testing is the gold standard for MODY diagnosis and should be pursued in patients with atypical features, as recommended by the American Diabetes Association 14
• The American Diabetes Association recommends consultation with a center specializing in diabetes genetics to interpret mutations and guide treatment 14